Interface Communications wins creative mandate for Seacod

The incumbent on the business is Sorento Healthcare Communications.

Draftfcb Ulka's second agency, Interface Communications has won the creative mandate for health supplement brand, Seacod.

The agency's Mumbai branch will handle this account. The agency spokesperson has confirmed the news to afaqs!. The ad spends are not yet frozen but it is learnt that the upcoming campaign will be a 360 degree effort that will exploit all possible media channels and consumer touch-points.

The incumbent on the business is Sorento Healthcare Communications. The agency was handling the creative duties for this brand till February, after which the account was put up on pitch. About three-four agencies participated in the process that was held in Mumbai.

Seacod is a product of Sanofi, a diversified global healthcare company. The product contains cod liver oil that provides the benefits of components such as Vitamin A and D, and Omega-3 fatty acids.

Sanofi has several interests in the healthcare field, including areas such as diabetes solutions, human vaccines, innovative drugs, rare diseases, consumer healthcare, emerging markets and animal health.

The company is listed in Paris and New York and is present in over 100 countries. In India, Sanofi operates through five entities, namely, Aventis Pharma, Sanofi-Synthelabo (India), Sanofi Pasteur India, Shantha Biotechnics and Genzyme India.

Earlier, Mumbai-based Universal Medicare had the license to manufacture and market the SevenSeas brand of cod liver oil from its UK parent for nearly three decades in India. Then, as Universal Medicare had its own Seacod brand, it merged the two in 2001 to call it SevenSeas Seacod.

In 2010, Aventis Pharma (part of the Sanofi Group) acquired Universal Medicare's marketing and distribution of branded nutraceutical formulations in India. As a result, while Universal Medicare returned the license for the SevenSeas brand to its UK owner, it retained the Seacod brand. Thus, today Seacod belongs to Aventis Pharma.